Cannabis and Hemp Industry Investment News

Cannabis Industry Press Releases and News Articles from the best investment journalist in the industry. Stay updated on all cannabis investment news from every online source, on MjInvest.com

Innocan Pharma bring significant update on Injectable CBD delivery system program

Innocan Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive with news the company has provided an update on their Injectable CBD delivery system that allows control release.

Bincovich telling Proactive some of the recent works done to prove the efficacy of the project and also a bit of detail of the man leading the project, Prof Chezy Barenholz from the Hebrew University.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

Continue reading
  9 Hits

Lexaria Bioscience agrees to sell non-pharmaceutical THC related assets for 3.85 million

Lexaria Bioscience (CSE: LXX- OTC: LXRP) CEO Chris Bunka joined Steve Darling from Proactive with news the company has agreed to sell certain non-core, non-pharmaceutical THC-related business assets to Hill Street Beverage for 3.85 million Canadian.

Bunka also told Proactive “Hill Street is acquiring royalty-free and perpetual global rights including relicensing rights of Lexaria's DehydraTECH technology” He also said Lexaria retains full ownership of its DehydraTECH technology.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

Continue reading
  15 Hits

Lexaria Bioscience sells THC-related assets for C$3.85 million to Hill Street Beverage Company ahead of possible US listing

Hill Street will gain exclusive global rights to Lexaria’s DehydraTECH technology for use in non-pharmaceutical products that contain over 0.3% THC, while Lexaria will retain full ownership of DehydraTECH

Lexaria plans to focus on regulated pharmaceutical and medical market segments

Lexaria Bioscience Corp () () is getting out of the THC business in preparation for a US listing, it said Thursday.

The biotechnology company has agreed to sell certain non-core, non-pharmaceutical THC-related assets owned by its subsidiary Lexaria Canpharm ULC for C$3.85 million to Hill Street Beverage Company Inc (), in which Lexaria owns a large position.

Hill Street will gain exclusive global rights to Lexaria’s DehydraTECH technology for use in non-pharmaceutical products that contain over 0.3% THC, while Lexaria will retain full ownership of DehydraTECH as well as the rights to use it with THC and other cannabinoids for pharmaceutical purposes.

READ: Lexaria lays out strategy for advancing DehydraTECH drug delivery technology in 2021

Hill Street and Lexaria also agreed to replace previous agreements with a global non-exclusive license that gives Hill Street the right to produce non-pharmaceutical CBD products with less than 0.3% THC using the DehydraTECH technology for a period of ten years in exchange for a yet-to-be determined royalty to Lexaria.

Continue reading
  15 Hits

Innocan Pharma launches two studies on animals examining therapeutic efficacy of its CBD-loaded liposome platform technology

The studies follow the results of previous studies that demonstrated the prolonged release of CBD for at least three weeks into the blood of mice and rats after a single injection

The new studies will be conducted by the Hebrew University of Jerusalem

Innocan Pharma Corporation () (FRA:IP4) announced the launch of two therapeutic studies on small and large animals examining the therapeutic efficacy of its CBD-loaded liposome platform technology (LPT) in relevant diseases.  

In a statement Monday, the company said these studies follow the results of previous studies that demonstrated the prolonged release of CBD (cannabidiol) for at least three weeks into the blood of mice and rats after a single injection. The new studies will be conducted by the Hebrew University of Jerusalem.

Innocan noted that the original study, which was led by Dr Ahuva Cern, senior researcher at the Hebrew University, found significant amounts of CBD in mice's blood and muscles up to 21 days after they were injected intramuscular with a single injection of CBD using LPT. The same findings were also demonstrated in rats.

READ: Innocan Pharma reaches agreement to sell its CBD product lines in Germany

These results, the company said, are substantial when compared to oral or smoking administration of CBD, in which CBD was found in the blood only for a period of up to 36 hours after one administration.

Continue reading
  14 Hits

Innocan Pharma reaches agreement to sell its CBD product lines in Germany

Innocan Pharma says its distribution agreement with German company iAmHealth Distribution UG is one of several such agreements it has signed in Europe

Innocan Pharma believes iAmHealth will provide a premier distribution channel for its SHIR and Relief & Go product lines

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) announced Wednesday that its wholly-owned Israeli subsidiary has entered into a distribution agreement with German company iAmHealth Distribution UG, a CBD products provider, to sell Innocan’s SHIR Beauty and Relief & Go product lines in Germany.

iAmHealth will distribute Innocan's cosmetic CBD products on a non-exclusive basis, immediately following the completion of all registration and regulatory requirements in Germany.

Innocan Pharma CEO Iris Bincovich said in a statement: "We are excited to start our product distribution in Germany. This is one of several distribution agreements that we have signed in Europe. I believe iAmHealth will provide a premier distribution channel for our SHIR and Relief & Go product lines."

READ: Innocan Pharma says its R&G Relief & Go CBD Spray product successfully passes EU safety requirements

iAmHealths Managing Director Nina Wlodarczyk added: "Our iAmHealth team comes from the medical industry with research based on science. As cannabidiol (CBD) became more available and gained popularity in Germany, we wanted to make our contribution and create a place for all of our existing customers, as well as people who are looking for new products they can trust, and with a high level of efficacy. We believe Innocan, as a pharmaceutical oriented company, is the perfect fit to complement the range of our existing products that we offer to the German consumer."

Continue reading
  24 Hits

Lexaria lays out strategy for advancing DehydraTECH drug delivery technology in 2021

DehydraTECH works by making active ingredients like CBD more easily absorbed into the bloodstream when ingested orally

Lexaria Bioscience Corp (OTC:LXRP) (), the developer of the patented DehydraTECH drug delivery platform, laid out its strategic initiatives for 2021 on Thursday, showing a focus on the regulated pharmaceutical and medical market segments. 

The company said it will concentrate on four core areas for DehydraTECH when pursuing out-licensing strategies with existing drug manufacturers:

Heart disease, including hypertension, utilizing CBD; Reduced-risk methods of delivering non-combusted nicotine; Improving antiviral drug delivery for applications that include Covid-19, influenza, herpes, hepatitis and AIDS; and Hemp-based CBD business-to-business applications

READ: Lexaria Bioscience says volume of DehydraTECH-enabled CBD powders processed is exceeding all expectations

With regard to CBD, Lexaria demonstrated in a 2019 pilot human clinical study that DehydraTECH-processed CBD was associated with a statistically significant slight decrease in human blood pressure.

Generic CBD is known to have poor absorption characteristics, the company said, and typically only about 6% of what is orally ingested actually finds its way into blood circulation. Lexaria's technology has shown an ability to increase absorption by between 100% to 500%.

The company is planning to launch a second exploratory human clinical study intended to expand on the original study. If the study is successful, Lexaria will begin outreach to the cardiovascular disease drug industry. 

Continue reading
  24 Hits

Innocan Pharma says its R&G Relief & Go CBD Spray product successfully passes EU safety requirements

The product also has received a Cosmetic Product Safety Report for product marketing in the EU

The spray combines the known benefits of active ingredients such as menthol and camphor with CBD and magnesium to help the body relax and recover for sport-performing professionals

Innocan Pharma Corporation () (FRA:IP4) has announced that its R&G Relief & Go CBD Spray product has successfully passed detailed safety assessment requirements of the European Parliament and the Council on Cosmetic Products. 

The product also has received a Cosmetic Product Safety Report (CPSR) for product marketing in the EU, the company said in a statement Wednesday. 

READ: Innocan Pharma announces publication of two scientific articles supporting its CLX therapy for COVID-19-infected lungs

Wholly-owned subsidiary Innocan Israel’s patent-pending unique formulation spray combines the known benefits of active ingredients such as menthol and camphor with CBD and magnesium (more than 40% in the formula) to help the body relax and recover for sport-performing professionals.

Innocan Pharma noted that Nir Avram, the subsidiary’s CTO, has over 30 years of experience as a senior consultant in the area of pharmaceuticals and cosmetics. Avram consults in diverse areas of expertise including pharmaceutical and cosmetic innovations, generic formulations, and synthesis of novel materials, in connection with start-ups and established companies.

Continue reading
  28 Hits

Canntab Therapeutics received purchase order from Australia while also taking part in research study

Canntab Therapeutics (CSE: PILL-OTCQB: CTABF) CFO Richard Goldstein joined Steve Darling from Proactive Vancouver with news the company has announced the launch of its suite of hard pill cannabinoid formulations in Australia with its partner CANN Global Ltd.

Goldstein takes Proactive through the first deal of the company overseas and he also shares news Canntab will be taking part in Australia's largest observational study ever undertaken for medical cannabis.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

Continue reading
  70 Hits

Canntab to launch in Australia and take part in the nation’s largest cannabis research study

The Canadian company will soon ship its suite of hard pill cannabinoid formulations to Australia, to be distributed by its partner CANN Global

Through its partner in Australia, Canntab Therapeutics will participate in the Cannabinoid Medicine Observational Study that will collect data from nearly 20,000 patients over five years

Canntab Therapeutics Limited () (OTCQB:CTABF) (FRA:TBF1) announced the impending launch of its suite of hard pill cannabinoid formulations in Australia with its partner CANN Global Limited () (FRA:54A). 

In a statement on Monday, the Canadian biopharma company which makes a suite of hard pill cannabinoid and terpene blends in multiple doses, said CANN Global, through its management partnership with Medcan Australia Pty Ltd, has received an import permit and has placed an initial order for Canntab's products. 

In the meantime, Canntab is applying for an export permit with Health Canada, which will allow it to fulfil the purchase order. The company intends to ship its suite of patented and patent-pending products — THC, CBD and THC/CBD combination hard pill formulations — to CANN Global before the end of 2020. CANN Global will then widely distribute Canntab’s products to medical distributors, doctors, pharmacies, and hospitals in Australia.

READ: Canntab Therapeutics closes $1M purchase of cannabis-processing equipment and leasehold improvements from CMAX Technologies

Meanwhile, Applied Cannabis Research (ACR), which focuses on medical cannabis treatments, has launched Australia's largest study for medical cannabis. Canntab, through the pills it supplies to CANN Global Ltd, a direct participant in the study, will get involved in the clinical collaboration with major Australian hospitals to complete the Cannabinoid Medicine Observational Study (CMOS), that will collect data from nearly 20,000 patients over five years.

Continue reading
  28 Hits

NA Proactive news snapshot: Vuzix Corporation, True Leaf Brands, Ceylon Graphite, American Manganese UPDATE …

A glance at some of the day's highlights from the Proactive Investors US and Canada newswires

Your daily round-up from the world of Proactive

() announced Friday that Grupo Boticário, one of South America's largest cosmetic companies, is utilizing its M400 Smart Glasses at its Camacari manufacturing facility in Brazil. The company is using the Vuzix glasses to connect its remote specialists in product development with the factory operators, who receive expert audio and video support while executing production. Because the product is worn as glasses, the process is hands-free and doesn’t impact manufacturing productivity. Additionally, the productivity of the specialists also increases due to less time spent traveling, which also greatly reduces their carbon footprint.

True Leaf Brands Inc () (OTCPINK:TRLFF) (FRA:TLA) announced Friday positive news concerning the firm’s restructuring process - its creditors had unanimously approved True Leaf’s proposals. The approvals allow True Leaf’s businesses, which include True Leaf Cannabis Inc, True Leaf Brands and True Leaf Investments Corp, to emerge from their respective proposal proceedings so that financial backers Canguard Entities can acquire the assets and shares of the companies.

() (OTCMKTS:CYLUF) (FRA:CCY) announced on Friday that it has closed the first tranche of its private placement with strong interest from a new strategic investor group. On October 19, Ceylon Graphite unveiled plans to raise up to C$4.5 million through a private placing, to accelerate its commercial operations.  In a statement, the miner said it offered an aggregate of 30,163,566 units at a price of $0.0875 per unit for gross proceeds of $2,639,312.  The second closing for the balance of the offering is likely to happen around October 28.

American Manganese Inc () (OTCPINK:AMYZF) (FRA:2AM) said Friday that there was continued recognition of the strategic importance of the Wenden manganese ore stockpile in Arizona and the recently awarded grant to the company from the United States Defense Logistics Agency (DLA).  This week, the DLA awarded American Manganese a grant to work on the US government's manganese ore stockpile located near Wenden, Arizona, with the goal of producing electrolytic manganese metal (EMM) for the nation. The DLA manages combat logistics across all US Armed Services and oversees the US National Defense Stockpile (NDS).

Continue reading
  32 Hits

NA Proactive news snapshot: Innocan Pharma, Metalla Royalty & Streaming, NexTech AR Solutions, American Manganese UPDATE…

A glance at some of the day's highlights from the Proactive Investors US and Canada newswires

Your daily round-up from the world of Proactive

Innocan Pharma Corporation () (FRA:IP4) announced Friday the recent publication of two scientific articles supporting its approach of using CBD-Loaded Exosomes (CLX) for the treatment of coronavirus (COVID-19). The company said the first paper entitled "Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients", was published in the Journal of Stem Cell Research & Therapy on October 15. It outlined that mesenchymal stem cells (MSCs) and their exosomes have potential therapeutic functions in the handling of COVID-19.

(NYSEAMERICAN:MTA) () said it has acquired a 1% net smelter return royalty (NSR) on Minera Alamos' () La Fortuna gold mine project in Durango State, Mexico, where construction is expected to begin in 2022. The royalty and streaming group has exercised its option with Alamos Gold Corp (NYSE:AGI) (), which owns the NSR, for a total consideration of US$1 million.

NexTech AR Solutions Corp () () (FRA:N29) announced Friday that the United Nations Educational, Scientific and Cultural Organization (UNESCO) has chosen InfernoAR for its virtual High-Level Futures Literacy Summit to be held December 8-12. The summit is a public event designed to showcase futures literacy, which UNESCO defines as “knowing how to use the future,” through 80 virtual booths, conversations with world leaders and futures literacy activities, all fueled by NexTech’s augmented reality (AR) technology.

American Manganese Inc () (OTCPINK:AMYZF) (FRA:2AM) said Friday that there was continued recognition of the strategic importance of the Wenden manganese ore stockpile in Arizona and the recently awarded grant to the company from the United States Defense Logistics Agency (DLA).  This week, the DLA awarded American Manganese a grant to work on the US government's manganese ore stockpile located near Wenden, Arizona, with the goal of producing electrolytic manganese metal (EMM) for the nation. The DLA manages combat logistics across all US Armed Services and oversees the US National Defense Stockpile (NDS).

Continue reading
  29 Hits

NA Proactive news snapshot: Innocan Pharma, Metalla Royalty & Streaming, NexTech AR Solutions, American Manganese …

A glance at some of the day's highlights from the Proactive Investors US and Canada newswires

Your daily round-up from the world of Proactive

Innocan Pharma Corporation () (FRA:IP4) announced Friday the recent publication of two scientific articles supporting its approach of using CBD-Loaded Exosomes (CLX) for the treatment of coronavirus (COVID-19). The company said the first paper entitled "Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients", was published in the Journal of Stem Cell Research & Therapy on October 15. It outlined that mesenchymal stem cells (MSCs) and their exosomes have potential therapeutic functions in the handling of COVID-19.

(NYSEAMERICAN:MTA) () said it has acquired a 1% net smelter return royalty (NSR) on Minera Alamos' () La Fortuna gold mine project in Durango State, Mexico, where construction is expected to begin in 2022. The royalty and streaming group has exercised its option with Alamos Gold Corp (NYSE:AGI) (), which owns the NSR, for a total consideration of US$1 million.

NexTech AR Solutions Corp () () (FRA:N29) announced Friday that the United Nations Educational, Scientific and Cultural Organization (UNESCO) has chosen InfernoAR for its virtual High-Level Futures Literacy Summit to be held December 8-12. The summit is a public event designed to showcase futures literacy, which UNESCO defines as “knowing how to use the future,” through 80 virtual booths, conversations with world leaders and futures literacy activities, all fueled by NexTech’s augmented reality (AR) technology.

American Manganese Inc () (OTCPINK:AMYZF) (FRA:2AM) said Friday that there was continued recognition of the strategic importance of the Wenden manganese ore stockpile in Arizona and the recently awarded grant to the company from the United States Defense Logistics Agency (DLA).  This week, the DLA awarded American Manganese a grant to work on the US government's manganese ore stockpile located near Wenden, Arizona, with the goal of producing electrolytic manganese metal (EMM) for the nation. The DLA manages combat logistics across all US Armed Services and oversees the US National Defense Stockpile (NDS).

Continue reading
  27 Hits

Innocan Pharma announces publication of two scientific articles supporting its CLX therapy for COVID-19-infected lungs

One article demonstrated the non-psychoactive reagent in cannabis (CBD) can significantly reduce the lung damage induced by cytokine storms

A product is planned to act as a 'guided missile' to the infected tissues, as the Exosomes migrate to Inflamed zones that are carrying CBD

Innocan Pharma Corporation () (FRA:IP4) announced Friday the recent publication of two scientific articles supporting its approach of using CBD-Loaded Exosomes (CLX) for the treatment of COVID-19.  

The company said the first paper entitled "Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients", was published in the Journal of Stem Cell Research & Therapy on October 15. It outlined that mesenchymal stem cells (MSCs) and their exosomes have potential therapeutic functions in the handling of COVID-19.

Specifically, Innocan said the study demonstrated that exosomes have the ability to enhance alveolar fluid clearance and promote epithelial and endothelial recovery through secretion of protective factors.

READ: Innocan Pharma's cosmetic clinical study indicates 90% wrinkle reduction in volunteers using SHIR Premium CBD Facial Serum

The second paper entitled "Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome" was published in the Journal of Cellular and Molecular Medicine on October 15.

Continue reading
  21 Hits

Lexaria Bioscience says volume of DehydraTECH-enabled CBD powders processed is exceeding all expectations

As of October 21, Lexaria has already processed around 4.2 million servings and has confirmed purchase orders to process a total of over 8 million servings during the current fiscal quarter

Lexaria's DehydraTECH technology masks unwanted tastes, improves onset speed, and increases the bioavailability of active pharmaceutical ingredients

Lexaria Bioscience Corp () () announced Thursday that the volume of servings produced of its patented DehydraTECH-enabled CBD powders is expected to hit for 500% growth over the previous quarter.

On September 23, the company told investors it had received purchase orders for 4.4 million CBD servings of the powder, to be processed during the company’s fiscal first quarter of 2021, September 1 to November 30.

Now, processing rates have exceeded expectations, the company said, and as of October 21, Lexaria has already processed approximately 4.2 million servings and has confirmed purchase orders to process a total of over 8 million servings during the current quarter.

READ: Lexaria Bioscience wins first European patent related to its DehydraTECH technology

That new estimate represents over 500% volume growth from approximately 1.2 million CBD servings processed in the fiscal fourth quarter ended August 31, which itself reflected growth of 71% from the fiscal third quarter. One serving generally ranges from 10mg to 25mg of CBD, utilizing the company’s DehydraTECH processes.

Continue reading
  29 Hits

Lexaria Bioscience wins first European patent related to its DehydraTECH technology

The patent includes claims for improved oral delivery of cannabinoids, nicotine, non-steroidal anti-inflammatory drugs and vitamins to treat a range of diseases

DehydraTECH masks unwanted tastes, improves onset speed and increases the bioavailability of active pharmaceutical ingredients

Lexaria Bioscience Corp () () (CNSX:LXX.CN) announced Wednesday that it will receive its first-ever European patent related to its DehydraTECH technology. 

In a statement, the company said the European patent number 3164141 will be published in the European Patent Bulletin of November 11, entitled "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof" and includes claims for improved oral delivery of cannabinoids, nicotine, non-steroidal anti-inflammatory drugs (NSAIDs) and vitamins. 

In addition, this patent includes important methods of treatment claims for a broad range of disease conditions including the use of:

Cannabinoids to treat cardiac conditions such as hypertension and neurological diseases such as Alzheimer's and Parkinson's; Cannabinoids to treat metabolic disorders and substance abuse and addictions; Nicotine to treat tobacco dependence/addiction and neurological diseases; NSAIDs to treat a host of conditions involving pain, fever and inflammatory states; and Vitamins to treat conditions such as ataxia related to certain vitamin deficiencies

READ: Lexaria Bioscience updates on business relationship with Altria Ventures

Lexaria said priority is granted to certain dates in 2014 and 2015, strengthening its intellectual property (IP) claims compared to more recent competitors. This represents the first patent issuance in Europe under Lexaria's first patent family.

Continue reading
  90 Hits

Canntab Therapeutics closes $1M purchase of cannabis-processing equipment and leasehold improvements from CMAX Technologies

Canntab also closed a $300,000 deal with Pharmagenerics Solutions to purchase cannabis-processing equipment 

Canntab is focused on the manufacturing and distribution of hard pill cannabinoid formulations in multiple doses and timed-release combinations

Canntab Therapeutics Limited () (OTCQB:CTABF) has closed on the $1,018,000 purchase of cannabis-processing equipment and leasehold improvements from CMAX Technologies Inc in Ontario.  

In a statement Tuesday, Canntab said the purchase price was based upon third-party valuations it had ordered.  

The purchase price was satisfied through the issuance of 1,996,078 common shares of the company at $0.51 each. A deposit of 200,000 shares was paid to CMAX shortly after the execution of the asset purchase agreement. 

READ: Canntab Therapeutics wins its first US patent covering its multi-layer tablet cannabinoid formulations

Canntab also said it closed its binding asset purchase agreement with Pharmagenerics Solutions Inc (Pharma) to purchase cannabis-processing equipment. 

Continue reading
  28 Hits

Innocan Pharma says Relief & Go CBD spray delivered pain relief to 90% of participants in clinical study

After 20 minutes, 83% of participants noticed improvement, the company said, which jumped to 95% after an hour

Innocan's pain relief formulation contains a combination of magnesium oil, methyl salicylate, menthol and CBD, administered with a simple dose of spray, roll-on or lotion

Innocan Pharma Corporation () announced Monday that 90% of participants in a clinical study of the company’s Relief & Go over-the-counter (OTC) spray experienced a reduction in pain 24 hours after use.

The study, conducted by the Center for Podiatric Care & Sports Medicine in New York, included 18 people with pain ranging in area from the upper back to the feet.

After 20 minutes, 83% of participants noticed improvement, the company said, which jumped to 95% after an hour. After a full 24 hours, 90% described relief from pain.

READ: Innocan Pharma's cosmetic clinical study indicates 90% wrinkle reduction in volunteers using SHIR Premium CBD Facial Serum

Fifteen of the 18 participants would recommend the spray, the company said.

Continue reading
  26 Hits

Innocan Pharma's cosmetic clinical study indicates 90% wrinkle reduction in volunteers using SHIR Premium CBD Facial Serum

CEO Iris Bincovich said the SHIR Beauty & Science skincare brand combines the benefits of CBD into an innovative formula for fast-acting results

The clinical study was conducted by an independent lab at the UPTEC, Science and Technology Park of the University of Porto, in Portugal

Corporation () (FRA:IP4) said Friday that it has completed a cosmetic clinical study that showed a dramatic 90% to 95% reduction in facial skin wrinkles after a group of study participants used the company’s SHIR Premium CBD Facial Serum for a period of 28 days. 

The company said a group of 20 volunteers applied SHIR Facial Serum, which has 300 milligrams of cannabidiol, on a sustained basis twice a day for 28 days and saw very positive results. An overwhelmingly high percentage of volunteers saw a more even skin tone and a depigmenting effect after using the product. "The skin was also more moisturized," according to the clinical results.   

"Achieving these amazing results is due to the combination of active ingredients with a specific amount of CBD, which results in tremendous facial skin improvement,” Innocan CEO Iris Bincovich said in a statement.

READ: InnoCan Pharma is taking a true pharmaceutical approach to commercializing cannabinoids

“The SHIR Beauty & Science skincare brand combines the benefits of CBD's most effective ingredients into an innovative formula which is leading to visible fast-acting results. Each ingredient was carefully chosen to provide a synergistic effect, working in harmony with each other.”

Continue reading
  54 Hits

NA Proactive news snapshot: Dyadic International, Vuzix Corp, InnoCan, American Resources, Metalla Royalty & Streaming - UPDATE

A glance at some of the day's highlights from the Proactive Investors US and Canada newswires

() updated investors on the company's swift progress since it had turned its C1 gene technology towards addressing the coronavirus (COVID-19) pandemic. The Jupiter, Florida-based company said its C1 Rapid Recombinant Protein Manufacturing platform has demonstrated that it can produce monoclonal antibodies (mAbs) more “efficiently and faster” than existing CHO mAb technology. Dyadic said it has expressed a SARS-CoV-2 monoclonal antibody with a biotech company that is developing antibody cocktails to treat COVID-19 patients. "The recent successful use of monoclonal antibody cocktails for the treatment of COVID-19 has also highlighted important production and supply constraints. Our C1 platform has the potential to generate 3x to 4x greater quantities of monoclonal antibodies in the same timeframe when compared to the current production methods using CHO cells,” pointed out Dyadic CEO Mark Emalfarb.

 (), a supplier of raw materials, announced Monday that it is expanding the workforce at its Perry County Resources mining complex in Hazard, Kentucky. As it works toward restarting the PCR complex, American Resources is in the process of expanding the workforce there to roughly 76 underground mine and 16 preparation plant employees in the near-term, with a plan to grow to approximately 175 workers as the complex expands its production base.

(NASDAQ: VUZI) announced Monday that SHL Group (Scandinavian Health Ltd) has commenced deployment of its Vuzix M400 Smart Glasses to provide remote support, beginning with its Taiwan locations. Vizix said the COVID-19 pandemic requires SHL auditors to quarantine for two weeks, which makes it difficult and expensive to perform audits. With hands-free smart glasses from Vuzix, operational staff are now able to support audits remotely through peer-to-peer video calling over the M400 Smart Glasses. The COVID-19 pandemic has also made it very difficult for SHL to travel and gather for engineering training. 

Corporation () announced on Friday that the company had achieved a “major milestone” in developing its unique CBD-loaded Liposome Platform Technology (LPT) for injectable CBD. Very few active ingredients of CBD are absorbed into the body, thanks to liver enzymes, which destroy over 80% of the essential components. However, LPT can enable increased bioavailability, targeted towards a specific organ or body part, with precise time and dosage control. A study carried out on mice by the Hebrew University of Jerusalem, in Israel on Innocan's CBD-loaded LPT showed a “prolonged release” of CBD into the blood for “at least three weeks after one administration.”

Continue reading
  32 Hits

InnoCan Pharma is taking a true pharmaceutical approach to commercializing cannabinoids

Developing revolutionary injectable CBD delivery system Strategic partnership with Hebrew University to study Liposome Platform Technology Tie-up with Tel Aviv University company Ramot to look at treating coronavirus with CBD-loaded exosomes Over-the-counter topical CBD creams targeted for commercial sales in 2020

InnoCan Pharma Corporation () is taking a true pharmaceutical approach to commercializing cannabinoids (CBD) on a number of fronts.

The Israeli company is developing a revolutionary injectable CBD delivery system that facilitates targeted, controlled administration of cannabinoids into the bloodstream.

Very few active ingredients of CBD are absorbed into the body. At best, around 15% of CBD oil is absorbed when taken orally, but the average is closer to between 5% and 10%. The culprit being liver enzymes, which destroy over 80% of the essential components.

The group’s Liposome Platform Technology (LPT) is being developed in conjunction with the Hebrew University in Jerusalem by a team with serious experience in liposomal delivery systems. LPT can enable increased bioavailability, targeted towards a specific organ or body part, with precise time and dosage control.

InnoCan holds a globally exclusive license to commercialize the research results and products that stem from the technology. According to the company, LPT has the potential to become a licensing platform to large pharmaceutical companies either for CBD dosage or their own specific needs.

Continue reading
  32 Hits